Sign In

Hugh (Heungnam) Kim

Sr. Research Scientist at OmniAb

Professional Background

Albert Kim is a dedicated researcher with an impressive track record in the realm of molecular biology and antibody engineering. His significant contributions to the field have centered around the development of clinically useful monoclonal antibodies intended for therapeutic and diagnostic applications. Throughout his multifaceted career, Albert has been involved in various critical aspects of therapeutic antibody discovery, showcasing a breadth of expertise that includes target selection using data mining, production and purification of antigens in mammalian cells, and conducting functional studies of antibodies both in vitro and in vivo. His extensive experience encompasses high-throughput screening technologies, as well as innovative methodologies such as phage display and mammalian cell display.

Albert has also made remarkable strides in understanding and addressing complex cancer targets. He is adept at utilizing methods like hybridoma technology and B cell cloning to create sophisticated antibody libraries that lead to the discovery of novel therapeutic agents. Throughout his work, he has been committed to enhancing the efficacy and safety of therapeutic antibodies, transforming promising research ideas into valuable clinical solutions.

Having worked with various renowned organizations, Albert’s experience spans across multiple leadership roles, each contributing to his unique skill set. As a former Senior Research Scientist at OmniAb, Inc. and a Senior Scientist II at 3T Biosciences, he has played a pivotal role in advancing therapeutic antibody development. His long-standing association with significant research institutions, including multiple roles at the National Institutes of Health, underlines his commitment to pioneering research and therapeutic innovation.

Education and Achievements

Albert's academic journey began with a focus on Environmental Health Science, culminating in a Ph.D. from the prestigious University of Occupational and Environmental Health in Japan. This foundation has enabled him to delve deeply into various scientific disciplines, particularly as they pertain to the synthesis and application of therapeutic antibodies.

His ambitious research goals have fuelled a career enriched with notable achievements. These include the development of monoclonal antibodies that exhibit significant therapeutic effects in animal models, extensive in vitro functional studies, and the successful application of advanced bioassay techniques.

Achievements

Albert’s career has positioned him at the forefront of antibody engineering, with a diverse portfolio of skills and experiences. He is proficient in:

  • Phage Display/Mammalian Cell Display: These techniques are crucial for identifying and confirming potential therapeutic antibodies.
  • Antibody Library Construction: His expertise in creating extensive antibody libraries allows for a broader range of therapeutic candidates, increasing success rates in drug development.
  • High-Throughput B Cell Cloning: This allows for rapid identification of B cells producing monoclonal antibodies, streamlining the discovery process.
  • Hybridoma Technology: Albert utilizes this foundational technique to produce monoclonal antibodies for therapeutic purposes.
  • Recombinant Antibody/Proteins Production: His ability to produce antibodies and proteins recombinantly enhances the therapeutic applications of his work.
  • Cell Line Development and Cell-Based Bioassays: These are instrumental in evaluating the effectiveness of therapeutic antibodies in relevant biological contexts.
  • Microarray, Signaling Pathway Analysis, and Cancer Target Search with Data Mining: Albert employs sophisticated data analysis techniques to identify and validate cancer targets, ensuring a systematic approach to his research.

Through an impressive career trajectory that encompasses both academic and industry experiences, Albert Kim has made a lasting impact in therapeutic antibody research. His work is instrumental in advancing cancer treatment options and improving patient outcomes. With an unwavering commitment to scientific integrity and innovation, Albert is poised to continue contributing to the biopharmaceutical landscape, driving forward breakthroughs in antibody therapy.

Related Questions

How did Albert Kim develop his expertise in antibody engineering?
What motivated Albert Kim to focus on clinically useful monoclonal antibodies?
In what ways has Albert Kim contributed to cancer research through his work at OmniAb and other organizations?
How does Albert Kim utilize data mining in the selection of cancer targets for therapeutic antibodies?
What are the key challenges Albert Kim faces in the production of therapeutic antibodies?
Hugh (Heungnam) Kim
Add to my network

Location

San Francisco Bay Area